{
    "2021-03-29": [
        [
            {
                "time": "2021-02-16",
                "original_text": "Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 Patients",
                "features": {
                    "keywords": [
                        "Bamlanivimab",
                        "VIR-7831",
                        "Combo",
                        "Reduces",
                        "Viral Load",
                        "Low-Risk",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-02-16",
                "original_text": "UPDATE 1-Lilly-Vir's COVID-19 antibody combo reduces viral load in study",
                "features": {
                    "keywords": [
                        "Lilly-Vir",
                        "COVID-19",
                        "antibody",
                        "combo",
                        "reduces",
                        "viral load",
                        "study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-02-16",
                "original_text": "Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Vir",
                        "Glaxo",
                        "Phase 2",
                        "trial",
                        "combining",
                        "antibodies",
                        "reduced",
                        "viral load",
                        "70%",
                        "day 7"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-02-16",
                "original_text": "Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Vir Biotechnology",
                        "GSK",
                        "Positive",
                        "Topline Data",
                        "Phase 2",
                        "BLAZE-4 Trial",
                        "Bamlanivimab",
                        "VIR-7831",
                        "Low-Risk",
                        "Adults",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-02-16",
                "original_text": "This Stalwart's Growth Story Isn't Over Yet",
                "features": {
                    "keywords": [
                        "Stalwart",
                        "Growth Story"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}